Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of anthracycline-related cardiac dysfunction
PACTR202609859539586Phase 2Recruiting
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Prevention of asymptomatic anthracycline-related cardiac dysfunction. Started Sep 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on PACTR202609859539586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609859539586.